Alcon: Keratoconjunctivitis Sicca trials

The registry lists 28 Keratoconjunctivitis Sicca studies with Alcon as lead sponsor. 0 are open to participants now and 16 have results posted.

Phase 2 4Phase 3 2Phase 4 3No phase 19(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Phase 2b Study Evaluating the Safety and Efficacy of AR-15512 Ophthalmic Solution for the Treatment of Dry Eye DiseaseCompletedNCT04498182Phase 2Results posted
• Clinical Outcomes Following Treatment With SYSTANE® BALANCECompletedNCT02776670Not applicableResults posted
• Clinical Evaluation of Systane® Balance in Dry Eye SubjectsTerminatedNCT02511379Not applicableResults posted
• Evaluation of Clinical Outcomes After the Use of SYSTANE® HYDRATIONCompletedNCT02470429Not applicableResults posted
• Clinical Evaluation Following Use of SYSTANE® ULTRA in the Management of Dry EyeCompletedNCT02446015Not applicableResults posted
• Clinical Evaluation of Systane® Gel Drops in Dry Eye SubjectsCompletedNCT02380248Not applicableResults posted
• Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye SubjectsCompletedNCT01967147Not applicableResults posted
• Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface StainingCompletedNCT01863368Not applicableResults posted
• Efficacy and Safety Study of FID 119515ACompletedNCT01833117Not applicableResults posted
• SYSTANE® Family - Meibomian DeficiencyCompletedNCT01733745Not applicableResults posted
• SYSTANE® BALANCE Symptoms (OSDI) & Inflammatory BiomarkersCompletedNCT01733732Not applicableResults posted
• The Effect of SYSTANE® BALANCE on Tear Film Break Up Time in Dry Eye SubjectsCompletedNCT01718028Not applicableResults posted
• Evaluation of SYSTANE® BALANCE in Dry Eye Subjects With Lipid DeficiencyCompletedNCT01688726Not applicableResults posted
• Clinical Evaluation of a Daily Disposable Contact Lens in Symptomatic Weekly/Monthly Lens WearersCompletedNCT01614600Not applicableResults posted
• Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye SyndromeCompletedNCT01382225Phase 3Results posted
• Evaluation of Anti-Inflammatory Treatment in Dry Eye PatientsCompletedNCT01276223Phase 2Results posted
• Evaluation of Comfort in Subjects With Moderate Dry Eye DiseaseCompletedNCT04830956Not applicable
• Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye DiseaseCompletedNCT03492541Not applicable
• In Vivo Measurement of Corneal Epithelial Changes in Dry Eye PatientsCompletedNCT01483989Not applicable
• An Open-Label, Single-Center Study Evaluating the Effect of Systane Balance on Video Ocular Protection Index (OPI) and Blink Patterns in Patients Diagnosed With Dry EyeCompletedNCT01223040Not applicable
• Efficacy of Systane Ultra in Post Menopausal Women With Dry EyeCompletedNCT01105910Phase 4
• Efficacy of Systane Balance to Stabilize the Tear Film in Dry Eye SubjectsCompletedNCT01086774Phase 4
• Clinical Evaluation of the Causes of Contact Lens Related Dry EyeCompletedNCT00995189Not applicable
• Barrier Function Measurement in Dry Eye Patients After Using Systane Ultra for 30 DaysCompletedNCT00946777Not applicable
• A Study of AL-38583 Ophthalmic Solution 0.05%, 0.010% Versus AL-38583 Vehicle for Dry EyeCompletedNCT00893139Phase 2
• A Study of Hydroxypropyl Guar Galactomannan 0.25% (HPGG) Versus Vehicle in Dry Eye PatientsCompletedNCT00840268Phase 2
• Evaluate Artificial Tear Efficacy in Moderate to Severe Dry EyeCompletedNCT00724412Phase 4
• Phase II Study of AL-2178 (FID 109980) in the Treatment of Dry EyeCompletedNCT00471419Phase 3